Gamma-Secretase Inhibitor RO4929097

DRUG14 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Acoustic SchwannomaAdult Alveolar Soft Part SarcomaAdult Anaplastic (Malignant) MeningiomaAdult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic OligodendrogliomaAdult AngiosarcomaAdult Brain Stem Glioma

Phase 1

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

TerminatedNCT01071564

National Cancer Institute (NCI)Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative +5

Start: 2009-11-30End: 2014-06-30Updated: 2015-04-15

RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

CompletedNCT01119599

National Cancer Institute (NCI)Acoustic Schwannoma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma +26

Start: 2010-05-31Updated: 2015-09-29

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

CompletedNCT01131234

National Cancer Institute (NCI)Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma +49

Start: 2010-05-31End: 2014-09-30Updated: 2014-12-23

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

TerminatedNCT01149356

National Cancer Institute (NCI)Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma +4

Start: 2010-10-31End: 2013-04-30Updated: 2015-05-25

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

CompletedNCT01154452

National Cancer Institute (NCI)Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor +32

Start: 2010-06-30End: 2015-02-28Updated: 2018-08-15

RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

TerminatedNCT01193881

National Cancer Institute (NCI)Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer

Start: 2010-08-31End: 2015-08-31Updated: 2015-09-29

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

CompletedNCT01196416

National Cancer Institute (NCI)Recurrent Melanoma, Stage IV Skin Melanoma

Start: 2010-08-31End: 2015-08-31Updated: 2019-11-18

Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer

TerminatedNCT01198535

National Cancer Institute (NCI)Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma +7

Start: 2010-09-30Updated: 2015-05-18

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

TerminatedNCT01217411

National Cancer Institute (NCI)Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative +10

Start: 2010-10-01End: 2011-11-30Updated: 2024-11-19

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

CompletedNCT01218620

National Cancer Institute (NCI)Adult Solid Neoplasm

Start: 2010-09-30End: 2014-12-31Updated: 2014-12-23

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

TerminatedNCT01238133

National Cancer Institute (NCI)Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative +6

Start: 2010-12-31End: 2015-08-31Updated: 2015-09-04

Phase 2

A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy

CompletedNCT01141569

National Cancer Institute (NCI)Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer

Start: 2010-06-30End: 2013-12-31Updated: 2017-03-10

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

CompletedNCT01175343

National Cancer Institute (NCI)Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma +3

Start: 2010-07-31End: 2015-08-31Updated: 2017-05-24

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

WithdrawnNCT01251172

National Cancer Institute (NCI)DS Stage III Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage I Plasma Cell Myeloma +1

Start: 2010-12-31Updated: 2017-09-28

Related Papers

A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC).

2021-10-2829 citations